StockNow
Log in
U.S. Markets

Bristol-Myers-Squibb (BMY) says the US FDA has accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

StockNow breaking-news AI analysis

BMY's mezigdomide NDA acceptance marks a critical step for its CELMoD platform. Phase 3 SUCCESSOR-2 data shows a 52% risk reduction in RRMM progression, positioning mezigdomide as a potential new oral standard.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)